DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/64dc63/hospira_generics_c) has announced the addition of the "Hospira Generics Company Intelligence Report" report to their offering.
Hospira was created in 2004 as a spin-off from Abbott Laboratories. It essentially comprises Abbott's old Hospital Products division, selling generic injectables, medication delivery systems and infusion products. A major new focus is biosimilars, for which the company has conducted a number of agreements. The firms epoetin zeta product, Retacrit, gained EC approval in December 2007, and was launched in early 2008.
Annual sales in 2009 were worth US$3,879.3 million. This was an increase of 6.8% over 2008, when net sales stood at US$3,629.5 million. Net income for 2009 stood at US$403.9 million, a healthy increase of 25.9% over 2008, when net income stood at US$320.9 million.
Hospira is a leading supplier of generic injectables in the USA, with a product range of around 200 generic injectable products. Therapeutic areas include cardiovascular, anaesthesia, anti-infectives, analgesics and emergency. Hospira generally procures the active pharmaceutical ingredients in these products from third-party suppliers.
In September 2006, Hospira announced a friendly US$2 billion takeover of Mayne Pharma, an Australian generic injectable specialist. The deal was completed in February 2007; it cemented Hospira's leading position in the US and extended its presence into other markets.
In March 2009, Hospira announced Project Fuel, an initiative to improve the company's margins and fuel its growth. The project aims to optimise the firms product line, evaluate non-strategic assets and streamline its organisational structure. As part of this, around 10% of the current workforce will be cut.
In December 2009, Hospira announced an agreement to acquire India-based Orchid Chemicals & Pharmaceuticals' beta-lactam manufacturing facilities and equipment, along with an R&D facility and the firm's generic injectable product portfolio. The acquisition, which cost around US$400 million, was completed in 2010.
Key Topics Covered:
1. Executive Summary
4. Financial Results
5. Major Developments
6. Contact Details
- Mayne Pharma
- Zuellig Pharma
For more information visit http://www.researchandmarkets.com/research/64dc63/hospira_generics_c.
Source: Espicom Business Intelligence Ltd
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: United States Asia Pacific North America Illinois India
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical